PPT-Learning Objectives Summarize the latest evidence on poly ADP ribose polymerase (PARP)

knowledge Incorporate evidencebased research into clinical practice to improve patient outcomes competence Niraparib maintenance therapy in patients with platinumsensitive recurrent ovarian cancer using an individualized starting dose NORA a randomized doubleblind placebocontrolled phase III trial. Mark Sulkowski, MD. Associate Professor of Medicine . Johns Hopkins University School of Medicine . Limitations of PegIFN + Ribavirin . (with or without protease inhibitors). Antiviral activity is host + virus genotype dependent . Summer 2015. TEAM Teacher Evaluation Process. Day . 1. 2. Instruction. Planning. Environment. Agenda. 3. Day. Components. Day One. TEAM Overview. Diving into the Rubric. Collecting Evidence. Pre/Post. January 2015. TEAM Teacher Evaluation Process. Day . 1. 2. Instruction. Planning. Environment. Agenda. 3. Day. Components. Day One. TEAM Overview. Diving into the Rubric. Collecting Evidence. Pre/Post. --students should be able to:. a.) describe at the biochemical level the events that occur to go from gene to phenotype; . b.) identify different types of RNA, note their properties, how they are processed to yield a functional form, and their function in gene expression; . One sneeze can generate an aerosol of enough cold viruses to infect thousands of people!. Treatment of . Herpesviruses. . Varicella-zoster,. Cytomegalavirus,. Herpes simplex. Anti-metabolites . . “False” DNA building blocks . and Opportunities. This program will include a discussion . of off-label treatment and investigational agents not approved by the FDA for use . in the United States and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.. PARP Inhibitors: What Do We know?. PARP Inhibitors: What Do We Know? (cont). PARP Inhibitors: What Don't We Know ?. SOLO-1: Study Rationale and Design. [a]. Primary Endpoint and Other . R. esults. Time to Second Progression or Death (. Program Overview . Discussion Outline. DNA Repair. ABCs of DNA Repair. DNA Repair Defects in Cancer. DNA Repair Defects Can Be an Achilles' Heel. Synthetic Lethality and Cancer DNA Repair Defects. Increased Sensitivity of . Date, Semester. Criminal Justice Today. Criminal Law. Chapter 4. 4.1. Summarize the purpose, primary sources, and development of law.. Define the rule of law, including its importance in Western democratic societies.. actual. . video-recorded proceedings from the . live . CME event and may include the use of trade names and other raw, unedited content. . Mansoor Raza Mirza. NSGO: Nordic Society of Gynaecological Oncology. Five-year . survival. 15%. 30%. 40%. ?50%?. First use . of . cisplatin. First use . of . carboplatin. First use . of . Paclitaxel . First reports . of. bevacizumab. Positive evidence . for weekly paclitaxel in first line. About this template. This template is designed to help course developers write SMART learning objectives. This is the starting point of an effective eLearning . course . design. Setting clear objectives since the beginning will guide and organize the work for both you and the learner. Skipping this important step can lead to pointless courses serving merely as a waste of . Arsenic Contamination in Potable Water and an Assessment of Regulations. California State University Northridge; Department of Environmental and Occupational Health . Macario Perez, Ammar Witwit . and Antonio F. .